Investor Presentation. February 2015

Transcription

1 Investor Presentation February 2015

2 Cautionary Notes FORWARD LOOKING STATEMENTS This presentation and oral statements accompanying this presentation contain forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding Amyris s product pipeline, sizes of markets that may be addressed by Amyris s current and potential products, Amyris s expected product pipeline, expected cash inflows from collaborations and product sales, product revenue pipeline and potential size, financial trends and outlook, operation of production facilities, commercial relationships, and Amyris s projected financial results, including cash inflows, operating expenses, earnings and cash payback from a manufacturing plant, that involve risks and uncertainties. These statements and other forward-looking statements that may be provided in the presentation and/or oral statements accompanying it are based on management s estimates and current expectations and actual results and future events may differ materially due to changes in Amyris s business and various risks and uncertainties, including those associated with any delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris s reliance on third parties to achieve its goals, and other risks detailed in the Risk Factors section of Amyris s quarterly report on Form 10-Q filed on November 7, Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise. NON-GAAP MEASURES This presentation and oral statements accompanying this presentation contains both GAAP and non-gaap financial information, because the Company considers non-gaap information to be a helpful measure to assess its operational performance and for financial and operational decision-making. The Company's non-gaap financial information excludes stock-based compensation, loss on purchase commitments and write off of production assets, depreciation and amortization, gains and losses from changes in fair value of derivatives and debt extinguishment, but adds back accounts receivable, deferred revenue and funding associated with collaborations. A reconciliation of the non-gaap financial measures presented in this presentation to their GAAP equivalents, is provided in the Company s Q earnings press release dated November 7, Additionally, please note during this presentation, we may discuss historical non-gaap financial measures. For each non-gaap financial measure discussed a presentation of the most directly comparable GAAP financial measure and a reconciliation of the difference between the non-gaap financial measure discussed and the most directly comparable GAAP measure is available in the Investor Relations section of the Company s website at 2

3 The Industrial Bioscience Company Proven technology, multiple molecules Operating at industrial manufacturing scale Differentiated & proven business model KEY FINANCIAL OUTLOOK Renewable Products CAGR 100% Y-o-Y Cash Gross Margin Range 50-60% Molecules in Pipeline Over 20 Average Selling Price per Liter Near $10 AMYRIS BIOREFINERY IN BRAZIL COMPANY HIGHLIGHTS Founded in 2003 by post-doctoral fellows from the University of California, Berkeley Headquartered in the San Francisco Bay Area and with operations in Brazil 395 full-time employees (27% of US employees are PhDs) Over 135 issued patents and nearly 300 pending applications LEADING INVESTORS BIOLDING investment 3

4 Key Milestones Signed collaboration agreement with Total Signed collaboration agreements with Signed F&F collaboration with IFF Formed fuels joint venture with Total Expanded collaboration in farnesene-based polymers Added multiple new collaborations Signed collaboration agreement with Firmenich for F&F Secured downstream processing facility in the U.S. Awarded $8MM DARPA contract Further expanded Firmenich collaboration Sanofi begins production of anti-malarial drug Amyris-Total renewable jet fuel begins commercialization Launched IPO and listed on NASDAQ Amyris sells diesel in a bus fleet - Brazil Diesel de Cana TM First renewable jet fuel demo flight First commercial shipment from Brotas Advanced innovative collaboration to develop ingredients for F&F markets Expanded Firmenich collaboration Expanded partnership products VW partners with Amyris to promote automotive uses of renewable fuels Amyris-Total demo flight in Airbus 321 (Paris Air Show) Continued to expand squalane sales 4

5 Technology 5

6 Proven Technology Platform Target Market Characteristics Consumer Care Emollients Fragrances Price & Supply Volatility Consumer Demand for Naturals Build Strains Millions strains per month Mutagenesis, Meiosis & Automated Strain Engineering 120,000 strains per month 96-well Screening Test Strains and Processes 60 strains per month 0.5 & 2 Liter Fermentation 2 strains per month 300 Liter Fermentation & Recovery Manufacture 2 to 4 strains per year 200,000 Liter Fermentation & Recovery Biopharma Theraupeutic and Drug Discovery Perf. Materials Polymers Solvents and Fluids Fuels Diesel Jet Fuel Need for Higher Performance at Competitive Price Lubricants Base Oils Finished Lubricants LEADING COLLABORATION PARTNERS 6

7 Industrialization of Synthetic Biology Traditional Biotechnology Artisan approach to biology Limited capacity Limited data acquisition Error-prone, reproducibility problems Industrialized Synthetic Biology Scale-down, standardize, & automate 1000X capacity gain Economies of scale Automated data acquisition Total Quality Management Continuous improvement Perfect reproducibility Only ask each question once 7

8 Strain Development Improvements Farnesene Second Generation Farnesene First Generation Fragrance 1 Fragrance 2 Efficiency (Yield) Fragrance 3 8

9 Integrated Manufacturing PRODUCTION COST EVOLUTION ($/L, non-gaap) Lab 2 L Pilot Plant 300 L 10 0 $3/L Today Lab 2 L scale Pilot Plant 300 L Demo Plant 5,000 L Production 6 x 200,000 L 9

10 Business Model 10

11 Industry Leading Product Portfolio CONSUMER CARE PERFORMANCE MATERIALS RENEWABLE MOBILITY LUBRICANTS COSMETICS AROMAS squalane hemi squalane fragrance oils polymers diesel engine solvents jet transformer adhesives & coatings hydraulic 11

12 Current Addressable Market $1.6T Over $1 Trillion Total Addressable Market Ahead $212B Over $100 Billion Addressable Market at Current Commercial Performance $123B $40B $4B $9B $18B Emollients, Moisturizers, Film Formers F&F Ingredients Elastomers and Synthetic Rubbers & Plastic Additives Auto & Industrial Lubricants Bulk Polymers, Coatings, Adhesives and Polyolefins Jet Fuel Diesel Fuel 12

13 Business Model COLLABORATIONS COLLABORATION INFLOWS $60M to $70M Annual Over 20 new More than 20 molecules under molecules under contract contract with 1 to 3 new product 1-to-3 launch new per product year launches/year RENEWABLE PRODUCTS PRODUCTION & SALES 2X Annual Growth FUNDS THE BUSINESS PROVIDES REVENUE GROWTH AND EARNINGS UPSIDE 13

14 $1B Product Revenue Pipeline Pharma Nutraceuticals Agroscience Flavors, Cosmetics, Polymers Multiple Fragrances Vitamins Solid Farnesene Rubber*, Elastomers (e.g. sealants, adhesives) Fragrance Ingredients 3 from Farnesene 3 from New Strains* Liquid Farnesene Rubber* Cleaning Solvent Hemisqualane Jet Fuel Diesel Squalane Fragrance Oil #1 *Development in partnership Opportunity (Assessment) Co-Engineering (Feasibility) Current Engineering (Development) 2014 First Sales (Launch) Commercial Business (Ongoing Revenue) 14

15 Collaboration-to-Products in Practice Collaboration Inflows and Product Revenue (Non-GAAP) $M $90 $80 $70 $60 $50 $40 $30 $20 $10 $0 Fragrance #3 Fragrance #2 Fragrance #1 Collaboration Funding Inflow

16 Financials 16

17 Over $700M Invested to Date Millions $800 $700 $69 $28 $600 $37 $5 $43 $500 $88 $400 $91 $300 $133 $200 $48 $61 $100 $66 $- $21 $41 Series A Series B Series B- 1 Series C Series C- 1 Series D IPO 2010 Feb 2012 Winter 2012 Spring 2013 Fall 2013 Winter 2013 Spring

18 Capital Structure Leading Equity Holders Current Debt Breakdown by Maturity ($ in millions, as of June 2014) $306.3M Debt Breakdown by Holder ($ in millions, as of June 2014) Development Banks & Project Financing Hercules Term Loan TOTAL 78.8 Convertibles $53.4 Converts TOTAL R&D $25.0 Converts Fidelity Institutional Holders of Convertibles Temasek Convertibles Nov'14 Mar'15 Feb'17 Mar'17 Dec'17 Oct'18 Jan'19 Apr'19 May'19 Jul'22 Total Converts BNDES FINEP BNDES Debt Glycotech Pre-Export Hercules Tranche I Tranche II 144A TOTAL R&D Project Project Project Financing Financing Term Loan Fidelity Financing Converts Converts Converts Financing Financing NOTE: Equity ownership percentages are based on shares of common stock currently outstanding (excluding convertible notes); Debt breakdown for illustration purposes, loans from Development Banks 18 and Hercules are shown as bullet at maturity, although they have their principal amortizing during their terms. Debt does not include about $2.5 million in working capital.

19 Board of Directors John Doerr Philippe Boisseau Nam-Hai Chua* Patrick Yang HH Sheikh Abdullah bin Khalifa Al Thani BIOLDING INVESTMENTS Geoff Duyk Carole Piwnica Fernando Reinach Neil Williams John Melo * Dr. Chua is appointed by Temasek Holdings 19

20 Summary Leading industrial synthetic biology technology, transforming how materials are made across all sectors and the technology enabling sustainable growth for the world s leading brands Strong pipeline that supports long-term profitability and growth built on commercialization of first three molecules World class board and management team, supported by some of the leading global investors Growing product revenue growth and cash inflows from multi-year partner collaborations 20